Asialoglycoprotein Receptor-Targeted Superparamagnetic Perfluorooctylbromide Nanoparticles.
Animals
Asialoglycoprotein Receptor
/ antagonists & inhibitors
Fluorocarbons
/ chemistry
Hepatocytes
/ drug effects
Humans
Hydrocarbons, Brominated
/ chemistry
Ligands
Liver
/ drug effects
Liver Diseases
/ drug therapy
Liver Neoplasms
/ drug therapy
Magnetic Iron Oxide Nanoparticles
/ chemistry
Rats
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
02
2021
accepted:
24
05
2021
entrez:
16
6
2021
pubmed:
17
6
2021
medline:
24
12
2021
Statut:
epublish
Résumé
The decrease in asialoglycoprotein receptor (ASGPR) levels is observed in patients with chronic liver disease and liver tumor. The aim of our study was to develop ASGPR-targeted superparamagnetic perfluorooctylbromide nanoparticles (M-PFONP) and wonder whether this composite agent could target buffalo rat liver (BRL) cells in vitro and could improve GalPLL, a ligand of ASGPR, was synthesized by reductive amination. ASGPR-targeted M-PFOBNP was prepared by a film hydration method coupled with sonication. Several analytical methods were used to investigate the characterization and safety of the contrast agent in vitro. The in vivo MR The optimum concentration of Fe GalPLL/M-PFOBNP may potentially serve as a liver-targeted contrast agent for MR receptor imaging.
Sections du résumé
Background
The decrease in asialoglycoprotein receptor (ASGPR) levels is observed in patients with chronic liver disease and liver tumor. The aim of our study was to develop ASGPR-targeted superparamagnetic perfluorooctylbromide nanoparticles (M-PFONP) and wonder whether this composite agent could target buffalo rat liver (BRL) cells in vitro and could improve
Methods
GalPLL, a ligand of ASGPR, was synthesized by reductive amination. ASGPR-targeted M-PFOBNP was prepared by a film hydration method coupled with sonication. Several analytical methods were used to investigate the characterization and safety of the contrast agent in vitro. The in vivo MR
Results
The optimum concentration of Fe
Conclusions
GalPLL/M-PFOBNP may potentially serve as a liver-targeted contrast agent for MR receptor imaging.
Identifiants
pubmed: 34131415
doi: 10.1155/2021/5510071
pmc: PMC8181107
doi:
Substances chimiques
Asialoglycoprotein Receptor
0
Fluorocarbons
0
Hydrocarbons, Brominated
0
Ligands
0
perflubron
Q1D0Q7R4D9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5510071Informations de copyright
Copyright © 2021 Yang Li et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Pharmaceutics. 2020 Jan 29;12(2):
pubmed: 32013203
Mol Imaging Biol. 2017 Oct;19(5):723-730
pubmed: 28194629
Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):24-46
pubmed: 20685224
J Pharmacol Exp Ther. 1998 Oct;287(1):408-15
pubmed: 9765363
J Clin Invest. 2019 Jan 2;129(1):24-33
pubmed: 30601139
J Appl Physiol (1985). 2004 Jan;96(1):76-80
pubmed: 12949020
Biology (Basel). 2020 Dec 31;10(1):
pubmed: 33396223
J Control Release. 2007 May 14;119(1):52-8
pubmed: 17350131
Atherosclerosis. 2012 Jun;222(2):360-6
pubmed: 22494625
Ann Biomed Eng. 2009 Oct;37(10):1922-33
pubmed: 19184435
Front Immunol. 2018 Jan 25;9:44
pubmed: 29422896
MAbs. 2019 Aug/Sep;11(6):1122-1138
pubmed: 31122132
AJR Am J Roentgenol. 1990 Dec;155(6):1161-7
pubmed: 2122660
Hepatology. 1996 Jun;23(6):1631-41
pubmed: 8675187
Scientifica (Cairo). 2014;2014:746574
pubmed: 25024867
Magn Reson Imaging. 1990;8(5):637-46
pubmed: 1707120
Int J Pharm. 2008 Aug 6;360(1-2):197-203
pubmed: 18539417
Sci Rep. 2016 May 06;6:25377
pubmed: 27150943
World J Gastroenterol. 2011 May 28;17(20):2482-99
pubmed: 21633653
MAbs. 2017 Nov/Dec;9(8):1360-1369
pubmed: 28876162
Gastroenterology. 1984 Dec;87(6):1217-21
pubmed: 6092193
Ann Nucl Med. 2003 Sep;17(6):489-93
pubmed: 14575385
Acta Radiol. 2013 Apr 1;54(3):278-83
pubmed: 23319724
Biomaterials. 2019 Jun;206:73-86
pubmed: 30953907
World J Gastroenterol. 2003 Jun;9(6):1251-5
pubmed: 12800234
Eur J Radiol. 2009 May;70(2):274-85
pubmed: 19268515